Positive Culture Prior to Transperineal Prostate Biopsy Was Not Associated with Post-Biopsy Febrile Urinary Tract Infection Development.
prostate biopsy
transperineal
urinary tract infection
urine culture
Journal
Research and reports in urology
ISSN: 2253-2447
Titre abrégé: Res Rep Urol
Pays: England
ID NLM: 101576971
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
08
2021
accepted:
03
09
2021
entrez:
15
9
2021
pubmed:
16
9
2021
medline:
16
9
2021
Statut:
epublish
Résumé
To investigate the association between urine culture before transperineal prostate biopsy and post-biopsy febrile urinary tract infection (fUTI). We retrospectively reviewed 307 patients who underwent urine culture before transperineal prostate biopsy between April 2017 and September 2020. Patients with indwelling urinary catheters (n=7) were excluded. Urine culture was performed 1-3 days before the biopsy, and all patients received prophylactic cefazolin regardless of culture results. A urine culture was defined as positive if cell density was more than 1×10 Out of 300, seven patients (2.3%) had positive urine culture results before the biopsy. Age (p=0.077); prostate-specific antigen at diagnosis (p=0.267); prostate volume (p=0.78); number of biopsy cores (p=0.277); percentage of patients testing positive for cancer on biopsy (p=0.71); and percentages of patients with a history of biopsy (p>0.999), diabetes mellitus (p=0.604), and immunosuppressive medication use (p>0.999) were similar between the two groups. No patient in the positive urine culture group had post-biopsy fUTI. However, 1.7% (five patients) of the negative urine culture group had the disease (p>0.999) (four patients with prostatitis and one with pyelonephritis). Among them, two patients were diagnosed by urine culture at the time of post-biopsy fUTI. In asymptomatic patients, positive pre-biopsy cultures were not associated with the development of post-biopsy fUTI.
Identifiants
pubmed: 34522689
doi: 10.2147/RRU.S333724
pii: 333724
pmc: PMC8434925
doi:
Types de publication
Journal Article
Langues
eng
Pagination
691-698Informations de copyright
© 2021 Tohi et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Clin Infect Dis. 2005 Mar 1;40(5):643-54
pubmed: 15714408
Urology. 2020 Feb;136:127-132
pubmed: 31705945
J Antimicrob Chemother. 2011 Mar;66(3):664-9
pubmed: 21172788
World J Urol. 2014 Apr;32(2):373-7
pubmed: 23743734
Urology. 2012 Mar;79(3):556-61
pubmed: 22386395
Int J Clin Oncol. 2015 Dec;20(6):1185-91
pubmed: 25917775
Urology. 2008 Feb;71(2):191-5
pubmed: 18308081
J Urol. 2011 Nov;186(5):1830-4
pubmed: 21944136
BJU Int. 2013 May;111(6):946-53
pubmed: 23464844
Int J Urol. 2019 Jun;26(6):655-660
pubmed: 30959574
J Urol. 1984 Apr;131(4):687-9
pubmed: 6708182
Prostate Cancer Prostatic Dis. 2008;11(2):134-8
pubmed: 17533394
Urology. 2013 Jun;81(6):1142-6
pubmed: 23726443
Int J Clin Oncol. 2020 Dec;25(12):2107-2114
pubmed: 32770439
Int Urol Nephrol. 2018 Jan;50(1):21-24
pubmed: 29170899
BJU Int. 2013 Sep;112(5):585-93
pubmed: 23551500
Int J Urol. 2008 Apr;15(4):319-21
pubmed: 18380819
Prostate Cancer Prostatic Dis. 2010 Sep;13(3):260-2
pubmed: 20368725
Asian J Androl. 2012 Mar;14(2):310-5
pubmed: 22101942
J Urol. 2012 Apr;187(4):1275-9
pubmed: 22341272
J Infect Chemother. 2014 Apr;20(4):232-7
pubmed: 24594451